|Tested species reactivity||Human, Mouse, Non-human primate, Rat|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Purified recombinant fragment of human GRK2 expressed in E. Coli.|
|Contains||0.03% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunofluorescence (IF)||1/200 - 1/1000|
|Immunohistochemistry (IHC)||1/200 - 1/1000|
|Western Blot (WB)||1/500 - 1/2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (Paraffin) (IHC (P))||See 1 publications below|
MA5-15840 targets GRK2 in IF, IHC, and WB applications and shows reactivity with Human, mouse, Non-human primate, and Rat samples.
The MA5-15840 immunogen is purified recombinant fragment of human GRK2 expressed in E. Coli. .
MA5-15840 detects GRK2 which has a predicted molecular weight of approximately 80kDa.
The product of this gene phosphorylates the beta-2-adrenergic receptor and appears to mediate agonist-specific desensitization observed at high agonist concentrations. This protein is an ubiquitous cytosolic enzyme that specifically phosphorylates the activated form of the beta-adrenergic and related G-protein-coupled receptors. Abnormal coupling of beta-adrenergic receptor to G protein is involved in the pathogenesis of the failing heart. Tissue specificity: Expressed in peripheral blood leukocytes
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
A multistep high-content screening approach to identify novel functionally relevant target genes in pancreatic cancer.
MA5-15840 was used in immunohistochemistry - paraffin section to develop a screening strategy to rationally select novel and relevant candidate genes to target therapeutically
|Buchholz M,Honstein T,Kirchhoff S,Kreider R,Schmidt H,Sipos B,Gress TM||PloS one (10:null)||2015|